# Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma

## TL;DR

This study identifies risk factors for mortality in low-grade B-cell lymphoma patients, emphasizing non-lymphoma-related causes like secondary malignancies and age.

## Contribution

The study introduces a competing risk analysis to better understand mortality causes in low-grade B-cell lymphoma.

## Key findings

- Secondary malignancies were linked to worse overall survival in LGBCL patients.
- Age over 60 years and male sex were associated with non-lymphoma-related mortality.
- Mantle cell lymphoma and anemia were linked to lymphoma progression-related death.

## Abstract

Low-grade B-cell lymphomas (LGBCLs) account for approximately 40% of non-Hodgkin lymphomas with low progression. LGBCL is divided into subgroups, which share common complications. Analyzing prognostic factors and mortality causes could improve patient survival; however, currently available models present limitations in discriminating the cause of death. Therefore, this study aimed to compare the prognostic factors and causes of death, such as secondary malignancies (SMs), aggressive histologic transformation (HT), and infectious complications, including coronavirus disease 2019 (COVID-19), in LGBCLs using a competing risk analysis.

This retrospective analysis included 1,047 adults with LGBCLs (follicular lymphoma, 689; marginal zone lymphoma, 312; mantle cell lymphoma [MCL], 46) diagnosed between January 2011 and December 2022 across seven centers. Competing risk models were employed to estimate cumulative incidence rates of lymphoma progression-related and non-lymphoma-related mortality.

Patients with SMs (3.8%) exhibited poorer overall survival than those without SMs, whereas HT and COVID-19 status did not impact survival outcomes in multivariate analysis. Analysis revealed an association of SMs, age > 60 years, male sex, pleural effusion, and elevated lactate dehydrogenase levels with worse non-lymphoma-related mortality. Moreover, age > 60 years, MCL, nodal MZL, and anemia were linked to poorer outcomes for lymphoma progression-related death.

The management of non-lymphoma-related risk factors, such as through early SM detection, is crucial for improving the survival of patients with LGBCLs.